Pooled analysis demonstrates favorable safety profile for risdiplam

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Apr 29 / Springer Healthcare

Let's Talk... SMA at EPNS 2022

Neuroscience Spinal Muscular Atrophy EPNS-2022

Description

In the second part of this episode, Laurent Servais discusses the findings from early-phase studies of anti-myostatin antibodies for the treatment of spinal muscular atrophy, and explores how these drugs may help to address some of the treatment challenges if the benefits are confirmed in phase 3 studies.

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.